FOLH1 and cancer: Additionally, 213Bi binding to the PSMA-617 antigen was investigated for the treatment of mCRPC-PSMA-targeted alpha therapy [70] and its use was found particularly appealing due to its ability to deliver high-energy radiation over short distances via α-particle and β-particle decay, which can effectively kill cancer cells while minimizing collateral damage to surrounding healthy tissue [71].